Inho Kim

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Andrew H. Wei, Pau Montesinos, Vladimir Ivanov et al. · Blood · 2020 · 725 citations · Full text

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Shaji Kumar, Simon J. Harrison, Michèle Cavo et al. · The Lancet Oncology · 2020 · 390 citations

Hematological Malignancy, Oncology, Hematology +7

Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease

Daniel Wolff, Corey Cutler, Stephanie J. Lee et al. · New England Journal of Medicine · 2024 · 106 citations

Anti-Inflammatory Effects of Total Isoflavones from Pueraria lobata on Cerebral Ischemia in Rats

Dong Wook Lim, Chang-Ho Lee, Inho Kim et al. · Molecules · 2013 · 57 citations · Full text

Lipid Peroxidation, Anti-inflammatory Effects, Cox-2 Expression +16

Blood culture-free ultra-rapid antimicrobial susceptibility testing

Tae Hyun Kim, Jun‐Won Kang, Haewook Jang et al. · Nature · 2024 · 57 citations

Antimicrobial Susceptibility, Health Sciences, Antibiotics +6